関節リウマチ治療におけるトファシチニブの単剤および併用治療の有効性、継続性および使用方法のオーストラリアでの実臨床評価

Clin Rheumatol. 2021. Epub ahead of print doi: 10.1007/s10067-021-05853-x

Real-world evidence suggests that monotherapy and combination therapy tofacitinib is an effective intervention in RA with persistence and effectiveness comparable to bDMARDs. Despite recommendations from EULAR that bDMARDs and tsDMARDs be used in combination with csDMARDs for the treatment of RA, it is estimated that up to a third of patients take their medication as monotherapy.This post hoc analysis of data from the Australian OPAL study by Bird, et al. aimed to describe the real-world effectiveness and treatment persistence among patients with RA treated with monotherapy and combination therapy tofacitinib and bDMARDs.

Keywords:


Publication thumbnail: 関節リウマチ治療におけるトファシチニブの単剤および併用治療の有効性、継続性および使用方法のオーストラリアでの実臨床評価
LinkedIn